Viking Therapeutics, Inc. Overview

Trial Radar AI Insights

Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops first-in-class and best-in-class therapies for metabolic and endocrine disorders. The company leverages its expertise in metabolism to target significant unmet needs in obesity, metabolic dysfunction-associated steatohepatitis (MASH/NASH), and rare diseases like X-linked adrenoleukodystrophy (X-ALD). By utilizing selective agonists and multi-receptor targeting, Viking aims to improve patient outcomes with therapies that offer superior efficacy and safety profiles compared to current standards of care.

• Company Snapshot: Founded 2012; HQ San Diego, California; Public (VKTX); https://www.vikingtherapeutics.com
• Scale & Stage: Employees ~50; Market Cap ~$3.60B; Clinical stage
• Research Focus: Obesity and weight management; Liver diseases (MASH/NASH); Rare endocrine disorders (X-ALD)
• Clinical Footprint: Active trials (lead sponsor): 1; Total participants: 5,600; Key geographies: United States, Puerto Rico

Therapeutic Focus

Viking Therapeutics prioritizes metabolic pathways that regulate lipid and glucose metabolism, energy expenditure, and tissue repair. The company’s strategic focus centers on dual receptor agonism and tissue-selective thyroid hormone receptor (TRβ) activation. This approach allows Viking to address the complex pathophysiology of obesity and fibro-inflammatory liver diseases while minimizing off-target effects in the heart and bone.

• Primary Focus Areas:

• Incretin Biology: Developing dual GLP-1 and GIP receptor agonists (VK2735) for obesity and related metabolic complications.

• Hepatology: Targeting THR-β (VK2809) to reduce liver fat and improve fibrosis in patients with MASH.

• Orphan Endocrine Diseases: Utilizing selective TRβ agonism (VK0214) to lower very long-chain fatty acids (VLCFAs) in X-ALD.

• Strategy & Capabilities:
  Viking’s core competency lies in small molecule and peptide engineering, specifically designing compounds with high receptor selectivity. The transition into late-stage development for its obesity program marks a shift toward large-scale global trials and commercial readiness. By securing multi-year manufacturing partnerships, Viking is positioning itself to compete in the high-volume metabolic market while maintaining a lean, research-intensive corporate structure.

Viking Therapeutics, Inc. Pipeline and Products

Late-Stage Pipeline (Phase 2b+)

Viking’s late-stage pipeline is dominated by VK2735, a potential blockbuster in the obesity space, and VK2809 for MASH. These assets are characterized by strong Phase 2 data demonstrating competitive weight loss and significant liver fat reduction.

Early-Stage Pipeline Highlights

Viking continues to expand its metabolic platform with novel mechanisms intended to improve the quality of weight loss and address patient populations who do not respond to traditional incretin therapies.

• Dual Amylin and Calcitonin Receptor Agonist (DACRA): This Phase I-ready program (IND filing expected Q1 2026) targets weight loss through non-incretin pathways. The platform focuses on lean mass preservation, addressing a critical drawback of current GLP-1 therapies.
• VK0214: A Phase Ib selective THR-β agonist for X-linked Adrenoleukodystrophy (X-ALD). This program has demonstrated significant reductions in plasma very long-chain fatty acids (VLCFAs) and is currently being evaluated for further development or partnering opportunities.
• VK5211: A Phase II selective androgen receptor modulator (SARM) for hip fracture recovery. While currently categorized as an inactive primary focus, it remains available for licensing to support muscle mass and bone mineral density recovery.

Viking Therapeutics, Inc. Clinical Trials Landscape

Trial StatisticsApply Below Filters

Viking Therapeutics currently manages 1 active interventional clinical trial as lead sponsor, targeting a total enrollment of 5,600 participants across 271 global sites. The clinical portfolio is heavily concentrated in Phase 3 development for weight loss, specifically focusing on adult and older adult populations. The company maintains a strong geographic presence in the United States and Puerto Rico, utilizing drug-based interventions to evaluate next-generation metabolic therapies.

Key Clinical Trial Updates

Viking reached a major milestone in November 2025 by completing enrollment for the VANQUISH-1 Phase 3 trial, which included over 4,500 patients. The companion trial, VANQUISH-2, focusing on obesity in patients with Type 2 Diabetes, is nearing full enrollment with completion expected in Q1 2026. To enhance patient convenience, Viking plans to introduce an auto-injector device into its clinical trials in early 2026. Additionally, the company expects to report topline data from its Phase 1 maintenance dosing study for VK2735 in Q3 2026, which will provide critical insights into long-term weight management and flexible dosing cycles.

Business Insights and Analysis

Business Development

Viking Therapeutics actively employs a strategy of internal development paired with strategic manufacturing and licensing agreements. In 2025, the company finalized a comprehensive multi-year agreement with CordenPharma to secure the large-scale production of VK2735 API and fill-finish capacity. Viking also maintains an exclusive worldwide license from Ligand Pharmaceuticals for the VK2809, VK0214, and VK5211 programs, ensuring full control over development and commercialization rights while benefiting from established intellectual property.

Financial Overview

As of early 2026, Viking Therapeutics maintains a robust financial position with approximately $706 million in cash and equivalents. This capital provides a multi-year runway to fund the global Phase 3 VANQUISH program and the initiation of pivotal trials for its oral obesity formulation. The company’s market capitalization of $3.60B reflects investor confidence in its metabolic pipeline, particularly following the successful End-of-Phase 2 meeting with the FDA for oral VK2735.

Clinical Trial Participation Guide

To explore opportunities for participation in Viking Therapeutics clinical trials, utilize the specialized tools available on Trial Radar:

• Participation Assistant: Use the "Simplify" tool to break down complex study protocols, "What to Expect" to understand the trial journey, and "Check Eligibility" to see if you meet the specific requirements for active obesity or MASH studies.
• Contacts & Locations: Navigate to this tab to view the 271 active sites, find the facility nearest to you, and obtain direct contact information for the study coordinators.

Explore Viking Therapeutics clinical trials

Find 9 studies.